Rheumatology Drugs Market Updates by 2031
Rheumatoid arthritis (RA) is a chronic inflammatory disease, which generally leads to disability, progressive joint deformity, and occasionally premature death. RA may affect many tissues and organs, but it principally attacks the joints, producing an inflammatory synovitis that often progresses to destruction of the articular cartilage and ankylosis of the joints. The treatment options available for rheumatoid arthritis are nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs) and biologic response modifiers (biologics).
MARKET DYNAMICS
The Rheumatology Drugs market is driving due to the rise in prevalence of arthritis, increasing acceptance of biopharmaceuticals, and presence of well-defined regulatory guidelines in developed economies. However, the accessibility of the treatment, patent expiration of blockbuster drugs and alternative treatment options for rheumatoid arthritis are projected to hamper the market growth.
MARKET SCOPE
The "Rheumatology Drugs Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Rheumatology Drugs market with detailed market segmentation by therapeutic molecule and route of administration. The Rheumatology Drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Rheumatology Drugs market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Rheumatology Drugs market is segmented on the basis of therapeutic molecule and route of administration. On the basis of therapeutic molecule, the market is categorized as pharmaceuticals, biopharmaceuticals. Pharmaceuticals segment is further segmented into NSAIDs, analgesics, DMARDs and corticosteroids. Biopharmaceuticals segment is further segmented into biologics and biosimilars. On the basis of route of administration, the market is categorized oral and parenteral..
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Rheumatology Drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Rheumatology Drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Rheumatology Drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Rheumatology Drugs market in these regions.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Rheumatology Drugs market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Rheumatology Drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Rheumatology Drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Rheumatology Drugs market in these regions.
MARKET PLAYERS
The report covers key developments in the Rheumatology Drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Rheumatology Drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for Rheumatology Drugs in the global market. Below mentioned is the list of few companies engaged in the Rheumatology Drugs market.
The report also includes the profiles of key players in Rheumatology Drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- AbbVie
- Regeneron Pharmaceuticals, Inc.
- Novartis International AG
- Pfizer Inc.
- Bristol-Myers Squibb.
- Hoffmann-La Roche AG
- Johnson and Johnson
- Boehringer Ingelheim GmbH
- UCB S.A.
- Amgen Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Rheumatology Drugs Market - By Therapeutic Molecule
1.3.2 Rheumatology Drugs Market - By Route of Administration
1.3.3 Rheumatology Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. RHEUMATOLOGY DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. RHEUMATOLOGY DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. RHEUMATOLOGY DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. RHEUMATOLOGY DRUGS - GLOBAL MARKET OVERVIEW
6.2. RHEUMATOLOGY DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. RHEUMATOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - THERAPEUTIC MOLECULE
7.1. OVERVIEW
7.2. THERAPEUTIC MOLECULE MARKET FORECASTS AND ANALYSIS
7.3. PHARMACEUTICALS
7.3.1. Overview
7.3.2. Pharmaceuticals Market Forecast and Analysis
7.3.3. NSAIDs Market
7.3.3.1. Overview
7.3.3.2. NSAIDs Market Forecast and Analysis
7.3.4. Analgesics Market
7.3.4.1. Overview
7.3.4.2. Analgesics Market Forecast and Analysis
7.3.5. DMARDs Market
7.3.5.1. Overview
7.3.5.2. DMARDs Market Forecast and Analysis
7.3.6. Corticosteroids Market
7.3.6.1. Overview
7.3.6.2. Corticosteroids Market Forecast and Analysis
7.4. BIOPHARMACEUTICALS
7.4.1. Overview
7.4.2. Biopharmaceuticals Market Forecast and Analysis
7.4.3. Biologics Market
7.4.3.1. Overview
7.4.3.2. Biologics Market Forecast and Analysis
7.4.4. Biosimilars Market
7.4.4.1. Overview
7.4.4.2. Biosimilars Market Forecast and Analysis
8. RHEUMATOLOGY DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. PARENTERAL
8.4.1. Overview
8.4.2. Parenteral Market Forecast and Analysis
9. RHEUMATOLOGY DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Rheumatology Drugs Market Overview
9.1.2 North America Rheumatology Drugs Market Forecasts and Analysis
9.1.3 North America Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.1.4 North America Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.1.5 North America Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Rheumatology Drugs Market
9.1.5.1.1 United States Rheumatology Drugs Market by Therapeutic Molecule
9.1.5.1.2 United States Rheumatology Drugs Market by Route of Administration
9.1.5.2 Canada Rheumatology Drugs Market
9.1.5.2.1 Canada Rheumatology Drugs Market by Therapeutic Molecule
9.1.5.2.2 Canada Rheumatology Drugs Market by Route of Administration
9.2. EUROPE
9.2.1 Europe Rheumatology Drugs Market Overview
9.2.2 Europe Rheumatology Drugs Market Forecasts and Analysis
9.2.3 Europe Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.2.4 Europe Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.2.5 Europe Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Rheumatology Drugs Market
9.2.5.1.1 Germany Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.1.2 Germany Rheumatology Drugs Market by Route of Administration
9.2.5.2 France Rheumatology Drugs Market
9.2.5.2.1 France Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.2.2 France Rheumatology Drugs Market by Route of Administration
9.2.5.3 Italy Rheumatology Drugs Market
9.2.5.3.1 Italy Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.3.2 Italy Rheumatology Drugs Market by Route of Administration
9.2.5.4 Spain Rheumatology Drugs Market
9.2.5.4.1 Spain Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.4.2 Spain Rheumatology Drugs Market by Route of Administration
9.2.5.5 United Kingdom Rheumatology Drugs Market
9.2.5.5.1 United Kingdom Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.5.2 United Kingdom Rheumatology Drugs Market by Route of Administration
9.2.5.6 Rest of Europe Rheumatology Drugs Market
9.2.5.6.1 Rest of Europe Rheumatology Drugs Market by Therapeutic Molecule
9.2.5.6.2 Rest of Europe Rheumatology Drugs Market by Route of Administration
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Rheumatology Drugs Market Overview
9.3.2 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.3.4 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.3.5 Asia-Pacific Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Rheumatology Drugs Market
9.3.5.1.1 Australia Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.1.2 Australia Rheumatology Drugs Market by Route of Administration
9.3.5.2 China Rheumatology Drugs Market
9.3.5.2.1 China Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.2.2 China Rheumatology Drugs Market by Route of Administration
9.3.5.3 India Rheumatology Drugs Market
9.3.5.3.1 India Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.3.2 India Rheumatology Drugs Market by Route of Administration
9.3.5.4 Japan Rheumatology Drugs Market
9.3.5.4.1 Japan Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.4.2 Japan Rheumatology Drugs Market by Route of Administration
9.3.5.5 South Korea Rheumatology Drugs Market
9.3.5.5.1 South Korea Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.5.2 South Korea Rheumatology Drugs Market by Route of Administration
9.3.5.6 Rest of Asia-Pacific Rheumatology Drugs Market
9.3.5.6.1 Rest of Asia-Pacific Rheumatology Drugs Market by Therapeutic Molecule
9.3.5.6.2 Rest of Asia-Pacific Rheumatology Drugs Market by Route of Administration
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Rheumatology Drugs Market Overview
9.4.2 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.4.4 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.4.5 Middle East and Africa Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Rheumatology Drugs Market
9.4.5.1.1 South Africa Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.1.2 South Africa Rheumatology Drugs Market by Route of Administration
9.4.5.2 Saudi Arabia Rheumatology Drugs Market
9.4.5.2.1 Saudi Arabia Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.2.2 Saudi Arabia Rheumatology Drugs Market by Route of Administration
9.4.5.3 U.A.E Rheumatology Drugs Market
9.4.5.3.1 U.A.E Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.3.2 U.A.E Rheumatology Drugs Market by Route of Administration
9.4.5.4 Rest of Middle East and Africa Rheumatology Drugs Market
9.4.5.4.1 Rest of Middle East and Africa Rheumatology Drugs Market by Therapeutic Molecule
9.4.5.4.2 Rest of Middle East and Africa Rheumatology Drugs Market by Route of Administration
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Rheumatology Drugs Market Overview
9.5.2 South and Central America Rheumatology Drugs Market Forecasts and Analysis
9.5.3 South and Central America Rheumatology Drugs Market Forecasts and Analysis - By Therapeutic Molecule
9.5.4 South and Central America Rheumatology Drugs Market Forecasts and Analysis - By Route of Administration
9.5.5 South and Central America Rheumatology Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Rheumatology Drugs Market
9.5.5.1.1 Brazil Rheumatology Drugs Market by Therapeutic Molecule
9.5.5.1.2 Brazil Rheumatology Drugs Market by Route of Administration
9.5.5.2 Argentina Rheumatology Drugs Market
9.5.5.2.1 Argentina Rheumatology Drugs Market by Therapeutic Molecule
9.5.5.2.2 Argentina Rheumatology Drugs Market by Route of Administration
9.5.5.3 Rest of South and Central America Rheumatology Drugs Market
9.5.5.3.1 Rest of South and Central America Rheumatology Drugs Market by Therapeutic Molecule
9.5.5.3.2 Rest of South and Central America Rheumatology Drugs Market by Route of Administration
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. RHEUMATOLOGY DRUGS MARKET, KEY COMPANY PROFILES
11.1. ABBVIE
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. REGENERON PHARMACEUTICALS, INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. NOVARTIS INTERNATIONAL AG
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. BRISTOL-MYERS SQUIBB.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. HOFFMANN-LA ROCHE AG
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. JOHNSON AND JOHNSON
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. BOEHRINGER INGELHEIM GMBH
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. UCB S.A.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. AMGEN INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
2. Regeneron Pharmaceuticals, Inc.
3. Novartis International AG
4. Pfizer Inc.
5. Bristol-Myers Squibb.
6. Hoffmann-La Roche AG
7. Johnson and Johnson
8. Boehringer Ingelheim GmbH
9. UCB S.A.
10. Amgen Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For